Physician profile
Judith Pendleton
NPI 1437153459
$1,021.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $108 · 2021: $186 · 2022: $174 · 2023: $257 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $165.85 | 2019-2024 | |
| Ultragenyx Pharmaceutical INC. | $127.63 | 2022-2024 | Crysvita |
| Glaxosmithkline, LLC. | $118.23 | 2019-2022 | |
| Sobi, INC | $112.62 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $105.33 | 2020-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Cranial Technologies, INC | $93.83 | 2020-2022 | |
| Kaleo, INC. | $92.24 | 2019-2022 | |
| Sanofi Pasteur INC. | $74.00 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $40.46 | 2023 | Flumist Quadrivalent |
| Seqirus USA INC | $31.95 | 2021 | |
| Ironshore Pharmaceuticals INC. | $31.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2020 | |
| Shire North American Group INC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.